South African drugmaker Aspen Pharmacare Holdings (APN:SJ) is considering additional acquisitions in Brazil and Latin America at large, reports the journal Invest in Brazil (IiB)). The firm is keen on growing its business not only Latin America, but also in other parts of the world such as Australia, where it is in the process of acquiring the pharmaceutical Division of Sigma Pharmaceuticals in a worth around $800 million (The Pharma Letter August 16), although a shareholders’ decision is still awaited.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze